Dive deeper

Open any topic for the full explanation, tables, clinical checkpoints, and references.

Full-length video Where can I learn more about Mohs and superficial radiation?

A complete visual guide

Watch the full explanation on YouTube A complete visual review with the supporting clinical context.
How do Mohs and superficial radiation solve the problem differently?

These Treatments Solve the Problem Differently

Mohs surgery removes the visible cancer and a thin layer of surrounding tissue, maps the specimen, and examines the peripheral and deep margins. If cancer remains, another layer is removed only from the involved location. The wound is repaired or allowed to heal after the examined margins are clear.1

Superficial radiation delivers ionizing radiation to the tumor and a planned field of surrounding skin over multiple fractions. Image-guided superficial radiation adds high-frequency ultrasound to estimate the visible tumor's depth and monitor the treated field. No tissue is removed for microscopic margin confirmation.2–4

This is more than a technical distinction. Mohs provides same-course histologic evidence about the tissue that was removed. Radiation provides a nonoperative treatment path whose success is established by clinical follow-up.

What can the evidence show about Mohs and radiation?

What the Evidence Can and Cannot Show

Surgery is the guideline-preferred primary treatment for most operable BCC and cSCC. Radiation is guideline-supported when surgery is not feasible or is declined, and as adjuvant treatment in selected higher-risk situations.2,5–7

A randomized trial of facial BCC found lower recurrence after surgery than radiotherapy and better long-term cosmetic ratings.8,9 The trial used older radiation techniques, so it should not be described as a modern randomized comparison of image-guided superficial radiation with Mohs.

Modern IG-SRT cohorts report high local-control estimates, including large series, but the evidence is predominantly retrospective. Follow-up, tumor selection, loss to follow-up, outcome definitions, and industry or device relationships need to be examined when interpreting the numbers.3,4,10–12 There is no modern randomized trial demonstrating that IG-SRT is equivalent to Mohs for Mohs-eligible high-risk, recurrent, aggressive-subtype, immunosuppressed, or perineural tumors.

Mohs evidence also has limits. Not every tumor has been studied in a randomized trial, and outcomes depend on tumor mix, surgeon, pathology technique, and follow-up. A balanced discussion should not turn either modality's best selected series into a guarantee for an individual patient.

How do visits and margin confirmation differ?

Treatment Burden and Margin Confirmation

Treatment Burden and Margin Confirmation
FeatureMohs surgerySuperficial radiation
How treatment is deliveredOne procedural course, sometimes with more than one mapped stage the same dayMultiple treatment visits over several weeks, depending on protocol
Margin informationPeripheral and deep margins from removed tissue are mapped and examinedNo excised margin specimen; response is monitored clinically and sometimes with ultrasound
AnesthesiaUsually local anesthesiaUsually no surgical anesthesia
RepairClosure, flap, graft, or natural healing after clearanceNo surgical wound at treatment, but the skin undergoes a radiation reaction
If recurrence occursAdditional surgery, radiation, or other care may be consideredSalvage surgery can be more complex in irradiated tissue; repeat radiation may be limited
Follow-upRecurrence surveillance plus scar and skin-cancer follow-upRecurrence surveillance plus monitoring of late radiation changes

For a healthy surgical candidate with a high-risk facial BCC or cSCC, immediate margin information and long-term surgical evidence often favor Mohs. For a frail patient who cannot tolerate surgery, a patient with a medical contraindication, or someone who declines surgery after understanding the differences, radiation may be a reasonable choice.

What skin changes can follow surgery or radiation?

Scars and Late Skin Changes

Mohs creates a wound. The resulting scar is often linear or follows a flap, graft, or natural-healing pattern. Scars usually evolve over months; early redness, firmness, or contour change is not the final result.

Radiation avoids an incision but does not leave untreated skin. Acute redness, scaling, crusting, or erosion can occur. Late changes can include hypopigmentation or hyperpigmentation, telangiectasia, atrophy, fibrosis, hair loss, texture change, and reduced tissue flexibility.2,8,9,13

The appearance of either outcome depends heavily on site, tumor size, treatment field, repair, skin type, healing, and time. “Noninvasive” should not be used as a synonym for “no lasting tissue effect.”

When might superficial radiation be a reasonable choice?

Who May Reasonably Choose Radiation

Radiation deserves serious consideration when:

  • surgery is medically unsafe or would create disproportionate burden;
  • the patient cannot tolerate the anticipated repair;
  • the tumor is in a setting where guideline-supported definitive radiation is reasonable;
  • the patient declines surgery after an accurate discussion of evidence and late effects; or
  • postoperative radiation is being considered for selected high-risk features.2,5–7

Radiation deserves extra caution when the patient is young, has a genetic radiosensitivity syndrome, has previously irradiated skin, has a tumor with poorly defined or deeply invasive extent, is unlikely to complete the treatment course, or would be difficult to salvage if recurrence occurs.2,5

What should I ask before choosing a treatment?

Questions to Ask Before Deciding

  1. Is my tumor lower, high, or very high risk?
  2. Which guideline supports each option for this exact tumor?
  3. How will we know the cancer is cleared?
  4. What is the expected number of visits?
  5. What are the acute and late skin changes?
  6. How long is the evidence follow-up for the technology being recommended?
  7. What happens if the cancer returns?
  8. Would prior radiation or future reconstruction change the balance?
  9. Are there financial relationships with the device or treatment being recommended?
What is the direct recommendation for this comparison?

The Direct Recommendation

When a patient is medically able to undergo surgery and the tumor is eligible for Mohs, Mohs is generally the stronger choice for a high-risk facial BCC or cSCC. It removes the cancer, examines the mapped margin during the operation, preserves uninvolved tissue, and gives the reconstructive team a cancer-free wound. Radiation can control selected tumors, but it treats a field without producing a complete surgical margin specimen and leaves recurrence to be recognized over time.

Radiation remains important for patients who cannot undergo surgery, decline it after an informed discussion, or need adjuvant treatment for selected high-risk features. That is a valuable role. It is not the same evidentiary position as saying modern superficial radiation has been proven equivalent to Mohs for Mohs-eligible high-risk disease; it has not.

What numbers help put these treatments in context?

Evidence by the Numbers

Evidence by the NumbersThe randomized facial-BCC comparison favored surgery

The randomized facial-BCC comparison favored surgery

0.7% vs 7.5% recurrence

Population
Older randomized trial of primary facial basal cell carcinoma
Outcome
Four-year recurrence after surgery versus conventional radiotherapy
Time horizon
Four years

What it means: For an operable facial BCC, surgery has the stronger randomized disease-control result and provides tissue for microscopic margin assessment.

Limitations: This trial compared surgery, not Mohs specifically, with older conventional radiotherapy; modern image-guided cohorts are not randomized equivalence trials.

References: 8

Frequently asked questions about Mohs and radiation

Frequently Asked Questions

Is image-guided superficial radiation the same as conventional radiation?

It uses superficial radiation plus high-frequency ultrasound for treatment planning and monitoring. It remains radiation therapy and does not provide a microscopic margin specimen.3,4

Does ultrasound prove the cancer is gone?

No. Ultrasound can help estimate the treated lesion's configuration, but it is not the same as examining excised tissue margins under a microscope.

Is Mohs always the better choice?

No. A patient who cannot undergo surgery or who makes an informed preference for radiation may reasonably choose it. The strongest recommendation depends on the tumor and patient.

Can radiation be used after surgery?

Yes. Adjuvant radiation can be considered in selected higher-risk cSCC or other situations when microscopic or clinical features suggest risk beyond local surgery alone.2,5

Will either treatment guarantee that the cancer never returns?

No. Both require long-term surveillance.

Who reviewed and authored this treatment comparison?
Portrait of Dr. Thomas L.H. Hocker

About the Author

Dr. Thomas L.H. Hocker is a Harvard- and Mayo Clinic-trained, triple board-certified dermatologist, Mohs surgeon, and dermatopathologist. He is the Founding Director of Dermatologic Surgery at the UMKC School of Medicine and University Health and an Iron Surgeon lecturer at the American Society for Dermatologic Surgery. His work focuses on Mohs surgery for melanoma, complex and rare skin tumors, and aesthetic reconstruction after skin-cancer treatment. He co-authored the best-selling textbook Review of Dermatology and created Skin Trust to give patients and clinicians free access to clear, current, evidence-based education.

Read Dr. Hocker's background and mission

Dr. Hocker earned his bachelor's degree with honors from Yale University, where he was inducted into Phi Beta Kappa. As a Winston Churchill Scholar, he then studied at the University of Cambridge and earned an M.Phil. in Organic Chemistry. He received his M.D. with honors from Harvard Medical School, where his research focused on melanoma genetics. He completed dermatology residency at Mayo Clinic, a dermatopathology fellowship at the University of Michigan, and a Mohs micrographic and reconstructive surgery fellowship at Mayo Clinic. He is board-certified in Dermatology, Dermatopathology, and Mohs Micrographic Surgery.

Dr. Hocker serves as the Founding Director of Dermatologic Surgery at the UMKC School of Medicine and University Health. He is an internationally invited lecturer and speaker who teaches about Mohs surgery for melanoma, complex and rare tumors, dermatopathology, and aesthetic reconstruction after skin-cancer treatment. He has also been selected as an Iron Surgeon lecturer by the American Society for Dermatologic Surgery. He is the co-author of Review of Dermatology, a best-selling dermatology review textbook, and he continues to teach and mentor medical students, residents, and physicians.

Skin Trust exists because Dr. Hocker believes access to excellent medical knowledge should not depend on geography, wealth, or proximity to a major academic center. After training at several of the world's leading institutions, he sees that education as both a gift and a responsibility: to translate current evidence, expert judgment, and hard-won clinical experience into guidance that patients, families, and clinicians can actually use.

The mission is to increase awareness, reduce avoidable suffering, and give every person equal access to trustworthy, up-to-date information that can help them make the best decisions for their life. Skin Trust also extends Dr. Hocker's lifelong commitment to teaching, writing, and mentoring medical students and residents as they build lives and careers of purpose and service.

For Dr. Hocker, this work is also an expression of faith. He regards the opportunities to learn at Yale, Cambridge, Harvard, Mayo Clinic, and the University of Michigan as blessings from God. Teaching, writing, mentoring, and building Skin Trust are ways to pay those blessings forward in service to patients, learners, and the broader community. His faith is the personal motivation to do this work carefully, generously, and with integrity; it is not a condition of using or benefiting from this free resource.

View Review of Dermatology Read Dr. Hocker's full biography
Where should I go next in the Patient Journey?

Next Steps in the Patient Journey

Continue with the guide that best matches the treatment being considered.

Continue with the question that fits you now

References for this Mohs and radiation comparison

References

  1. Tolkachjov SN, Brodland DG, Coldiron BM, et al. Understanding Mohs micrographic surgery. Mayo Clin Proc. 2017;92:1261-1271. PMID: 28778259.
  2. Likhacheva A, Awan M, Barker CA, et al. Definitive and postoperative radiation therapy for basal and squamous cell skin cancers: ASTRO guideline. Pract Radiat Oncol. 2020.
  3. Tran A, et al. Image-guided superficial radiation therapy for keratinocyte carcinoma. J Cancer Res Clin Oncol. 2023.
  4. Moloney M, et al. Multi-institutional outcomes of image-guided superficial radiation therapy. BMC Cancer. 2025.
  5. National Comprehensive Cancer Network. Basal Cell Skin Cancer. Version 2.2026.
  6. National Comprehensive Cancer Network. Squamous Cell Skin Cancer. Updated March 17, 2026.
  7. Kim JYS, Kozlow JH, Mittal B, et al. Guidelines for BCC and cSCC management. J Am Acad Dermatol. 2018.
  8. Avril MF, Auperin A, Margulis A, et al. Facial BCC: surgery or radiotherapy? Br J Cancer. 1997. PMID: 9218740.
  9. Petit JY, Avril MF, Margulis A, et al. Cosmetic results of surgery versus radiotherapy for facial BCC. Plast Reconstr Surg. 2000.
  10. Agha R, et al. Long-term registry outcomes after image-guided superficial radiation therapy. J Clin Med. 2024.
  11. Yu L, et al. Image-guided superficial radiation compared with historical radiation cohorts. BMC Cancer. 2023.
  12. Hruza GJ, et al. Superficial radiation therapy for nonmelanoma skin cancer: evidence and limitations. Dermatol Surg. 2024.
  13. van Hezewijk M, et al. Late skin effects after radiotherapy for nonmelanoma skin cancer. Radiother Oncol. 2010.